Harvard Bioscience (NASDAQ:HBIO) Releases Quarterly Earnings Results

Harvard Bioscience (NASDAQ:HBIO) announced its earnings results on Wednesday. The medical instruments supplier reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.03), Zacks reports. Harvard Bioscience had a negative net margin of 14.57% and a negative return on equity of 4.64%.

Harvard Bioscience Trading Down 4.9 %

NASDAQ:HBIO opened at $0.73 on Wednesday. The company has a fifty day moving average of $1.51 and a 200 day moving average of $2.11. Harvard Bioscience has a 52 week low of $0.55 and a 52 week high of $4.70. The firm has a market capitalization of $31.62 million, a P/E ratio of -2.18 and a beta of 1.46. The company has a quick ratio of 0.91, a current ratio of 2.06 and a debt-to-equity ratio of 0.52.

Institutional Trading of Harvard Bioscience

A hedge fund recently raised its stake in Harvard Bioscience stock. Bank of America Corp DE boosted its position in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 44.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 38,883 shares of the medical instruments supplier’s stock after purchasing an additional 11,948 shares during the quarter. Bank of America Corp DE owned about 0.09% of Harvard Bioscience worth $82,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 80.87% of the company’s stock.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.